Diacylglycerol acyltransferase inhibitor-1 is primarily used in research to study lipid metabolism and its regulation. It plays a significant role in inhibiting the enzyme diacylglycerol acyltransferase (DGAT), which is crucial for triglyceride synthesis. By blocking this enzyme, it helps in understanding the pathways involved in fat storage and energy balance. This inhibitor is also explored for its potential in treating metabolic disorders such as obesity and type 2 diabetes, as reducing triglyceride synthesis can lead to decreased fat accumulation and improved insulin sensitivity. Additionally, it is investigated for its effects on reducing liver steatosis, a condition characterized by excessive fat buildup in the liver. Its application extends to pharmaceutical development, where it serves as a tool for designing drugs targeting lipid-related diseases.